

CHAPTER 10

REFERENCES

- Adamson R. 1956. The genus *Galenia*. *Journal of South African Botany* **22** (3): 88 - 123
- Al-Fatimi M., Friedrich U., Jenett - Siems K. 2005. Cytotoxicity of plants in traditional medicine in Yemen. *Fitoterapia* **76**: 355 - 358
- Alamelu R. 2004. Immunology of tuberculosis. *Indian Journal of Medical Research*. **120**: 213 - 232
- Amabeoku G.J., Eagles P., Scott G., Mayeng I., Springfield E. 2001. Analgesic and antipyretic effects of *Dodonaea angustifolia* and *Salvia africana-lutea*. *Journal of Ethnopharmacology* **75** (2-3): 117 - 124
- American Hospital Formulary Services (AHFS) Drug Information. 2000. American Society of Health-System Pharmacists. pp 485 - 506
- American Thoracic Society. 1986. Treatment of tuberculosis and tuberculosis infection in adults and children: official statement. *American Review of Respiratory Disease* **134**: 355 - 363
- Andries K., Verhasselt P., Guillemont J., Gohlmann H.W., Neef J.M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E. 2005. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science* **307**: 223 - 227
- Arnold H.J., Gulumian M. 1984. Pharmacopoeia of traditional medicine in Venda. *Journal of Ethnopharmacology* **12**: 35 - 74
- Asres K., Bucar F., Edelsbrunner S., Kartnig T., Höger G., Thiel W. 2001. Investigations on antimycobacterial activity of some Ethiopian medicinal plants. *Phytotherapy Research* **15**: 323 - 326
- Avila H., Rivero J., Herrera F., Fraile G. 1997. Cytotoxicity of a low molecular weight fraction from *Aloe vera* gel. *Toxicon* **35** (9): 1423 - 1430

- Auvin C., Lezenven F., Blond A., Augeven-Bour I., Pousset J.L., Bernard Bodo B. 1996. Mucronine J, a 14-Membered Cyclopeptide Alkaloid from *Zizyphus mucronata*. *Journal of Natural Product* **59** (7): 676 - 678
- Ayyazian L.F. 1993. History of tuberculosis. In: Reichman LB. Hershfield (Eds.), Tuberculosis. Dekker, New York.
- Balick M.J. 1990. Ethnobotany and the identification of therapeutic agents from the rainforest. *Institute of Economic Botany* **154**: 22 - 39
- Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K.S., Wilson T., Collins D., de Lisle G., Jacobs W.R. 1994. InhA, a gene encoding a target for isoniazid and ethionamide in *M. tuberculosis*. *Science* **263**: 227 - 230
- Banki A., Jenei P., Richards G.M. 2000. *Mycobacterium tuberculosis* and its host cell, the macrophages.
- Bapela N.B. 2005. Isolation of naphthoquinones from the roots of *Euclea natalensis* and their *in vitro* antimycobacterial activity and toxicity. PhD. Thesis. University of Pretoria. South Africa.
- Bapela N.B., Lall N., Fourie P.B., Franzblau S.G., VAN Rensburg C.E.J. 2006. Activity of 7-methyljuglone in combination with antituberculosis drugs against *Mycobacterium tuberculosis*. *Phytomedicine* **3** (9-10): 630 - 635
- Barclay W.R., Ebert R.H., Le Roy G.V., Manthei R.W., Roth L.J. 1953. Distribution and excretion of radioactive isoniazid in tuberculosis patients. *Journal of American Medical Association* **151**: 1384 - 1388
- Barnes P.L., Modlin R.L., Ellner J.J. 1994. T-cell responses and cytokines. In: Bloom B.R. editor. *Tuberculosis: Pathogenesis, protection and control*. Washington, DC: ASM Press. 417 - 435
- Bartlett J.G., Dowell S.F., Mandell L.A., File T.M., Musher D.M., Fine M.J. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clinical Infectious Disease* **31**: 347 - 382
- Bartmann K. 1988. Anti-tuberculosis drugs. Springer-Verlag Berlin Heidelberg. Germany.
- Basel H.H. 1998. History of Tuberculosis. *Respiration* **65**: 5 - 15
- Basso L.A., Blanchard J.S. 1998. Resistance to anti-tubercular drugs. *Advance*

- Experiments in Medical Biology* **456**: 115 - 144
- Bastian I., Colebunders R. 1999. Treatment and prevention of multidrug-resistant tuberculosis. *Drugs* **58**: 633 - 666
- Berenbaum M.C., 1978. A method for testing synergy with a number of agents. *Journal of Infectious Disease* **137**: 122 - 130
- Beyers N. 1999. Tuberculosis. Wellcome Trust Workshop on Immunology, University of Cape Town, Cape Town.
- Bhave D.P., Wilson B., Muse III Carroll K.S. 2007. Drug targets in mycobacterial sulphur metabolism. *Infectious Disorders - Drug Targets* **7**: 140 - 158
- Biot C., Bauer H., Schirmer R.H., Davioud-Charvet E.J. 2004. 5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials. *Journal of Medicinal Chemistry* **47**: 5972 - 5983
- Bloom B.R., Murray. C.J.L. 1992. Tuberculosis: commentary on a re-emergent killer. *Science* **257**: 1055 - 1064
- Bloom B.R. 1994. Tuberculosis: pathogenesis, protection and control. *American Society of Microbiology*. Washington, DC.
- Bloom B. R. 2002. Tuberculosis – The Global view. *Journal of Medicine* **346**: 1434 - 1435
- Bobrowska-Hagerstrand M., Wrobel A., Mrowczynska L., Soderstrom T., Shirataki Y., Motohashi N., Molnar J., Michalak K., Hagerstrand H. 200. Flavonoids as inhibitors of MRPI-like efflux activity in human erythrocytes. A structure activity relationship study. *Oncology Research* **13**: 463 - 469
- Bohlin L. 1998. Natural products isolation. *Drug discovery today* **12** (3): 536 - 537
- Bohlmann F., Jakupovic J. 1979. Naturally occurring terpene derivatives. New sesquiterpene, triterpene, flavanone and other aromatic compounds from *Flourensia heterolepis*. *Phytochemistry* **18**: 1189 - 1194
- Borchardt J.K. 2002. Tuberculosis: Resurgence of a historic scourge. *Drug news and perspective* **15** (8): 535
- Bozeman L., Burman W., Metchock B., Welch L., Weiner M. 2005. Fluoroquinolone susceptibility among *Mycobacterium tuberculosis* isolates from the United States and Canada. *Clinical Infectious Disease* **40**: 386 - 391

- Brennan P.J. 1988. *Mycobacterium* and other actinomycetes, in *Microbial lipids*, **1**, (ed). Academic Press, London. 203 - 298
- British Thoracic Society. 1984. A controlled trial of 6 months chemotherapy in pulmonary tuberculosis, final report: results during the 36 months after the end of chemotherapy and beyond. *British Journal of Diseases of the Chest* **78** (4): 330 - 336
- Brzostek A., Sajduda A., Sliwinski T., Augustynowicz-Kopec E., Jaworski A., Zwolska Z., Dziadek, J. 2004. Molecular characterisation of streptomycin resistant *Mycobacterium tuberculosis* strains isolated in Poland. *International Journal of Tuberculosis and Lung Diseases* **8**: 1032 - 1035
- Caldwell C.G., Franzblau S.G., Suarez E., Timmermann B., 2000. Oleanane triterpenes from *Junillia tridens*. *Journal of Natural Product* **63**: 1611 - 1614
- Camus J.C., Pryor M.J., Medigue C., Cole S.T. 2002 Re-annotation of the genome sequence of *Mycobacterium tuberculosis* H37Rv. *Microbiology* **148**: 2967 - 2963
- Candy H.A., McGarry E.J., Pegel K.H. 1968. Constituents of *Syzygium cordatum*. *Phytochemistry* **7** (5): 889 - 890
- Cantrell C.L., Fischer N.H., Urbatsch L., McGuire M.S., Franzblau S.G., 1998. Antimycobacterial crude plant extract from South, Central and North America. *Phytomedicine* **5**: 137 - 145
- Cantrell C.L., Abate L., Fronczek F.R., Franzblau S.G., Quijano L., Fischer N.H., 1999. Antimycobacterial eudesmanolides from *Inula helenium* and *Rudbeckia subtomentosa*. *Planta Medica* **65**: 351 - 355
- Cantrell C.L., Franzblau S.G., Fischer N.H. 2001. Antimycobacterial plant terpenoids. *Planta Medica* **67** (8): 685 - 694
- Casenghi M. 2006. Development of new drugs for TB chemotherapy: Analysis of the current drug pipeline. PhD thesis.
- Casenghi M., Cole S.T., and Nathan C.F. 2007. New approaches to filling the gap in tuberculosis drug discovery. *PLoS Medicine* **4** (11): 293
- Cavaliere S.J., Biehle J.R., Sanders W.E. 1995. Synergistic activities of clarithromycin and antituberculosis drugs against multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy* **39** (7): 1542 - 1545

- Chan E.D., Iseman M.D. 2002. Current medical treatment for tuberculosis. *British Medical Journal* **325**: 1282 - 1286
- Chanwong S., Maneekan N., Makonkawkeyoon L., Makonkawkeyoon S., 2007. Intracellular growth and drug susceptibility of *Mycobacterium tuberculosis* in macrophages. *Tuberculosis* **87** (2): 130 - 133
- Clark D.W. 1985. Genetically determined variability in acetylation and oxidation: Therapeutic implications. *Drugs* **29**: 342 - 375
- Cobelens F.D.W., Helder E., Kimerling M.E., Mitnick C.D., Podewils L.J., Ramachandran R., Hans L. Rieder H.L., Weyer K., Zignol M. 2008. Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda. *PLoS Medicine* **5**(7): e150 Hans L. Rieder, Karin Weyer, and Matteo Zignol, on behalf of the Working Group on MDR-TB of the Stop TB Partnership.
- Collins F.M. 1998. *Mycobacterium* pathogenesis: a historical perspective. *Frontiers Bioscience* **3**: 123 - 132
- Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., Dye C. 2003. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. *Archives of Internal Medicine* **163**: 1009 - 1021
- Core Curriculum on Tuberculosis. 2000. Division of Tuberculosis Elimination, Centres for Disease Control and Prevention. Available on: <http://www.cdc.gov.nchstp/tb/pubs/corecurr/default.htm>
- Correa A., Mireya D. S., Tania R. D. S. 2005. *Drosera* (Droseraceae), in: Flora Neotropica, *Monograph* **96**, New York.
- Cragg G.M., Newman D.J. 2005. Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology* **100** (1-2): 72 - 79
- Crouch I.J., Finnie J.F., van Staden J. 1990. Studies on the isolation of plumbagin from *in vitro* and *in vivo* grown *Drosera* species. *Plant Cell, Tissue and Organ Culture* **21**: 79 - 82
- Crowle A. J., Sbarbaro J.A., Judson F.N., Douvas G.S., May M.H. 1984. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages. *The American Review of Respiratory Disease* **130** (5): 839 - 844
- Crowle A. J., Sbarbaro J.A., May M.H. 1985. The effect of ethambutol on tubercle

- bacilli within cultured human macrophages. *The American Review of Respiratory Disease* **132** (4): 742 - 745
- Crowle A. J., Sbarbaro J.A., May M.H. 1986. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. *The American Review of Respiratory Disease* **134**: 1052 - 1055
- Crowle A. J., Sbarbaro J.A., May M.H. 1988. Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. *Tubercle* **69** (1): 15 - 25
- Cynamon M.H., Sklaney M. 2003. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. *Antimicrobial Agents and Chemotherapy* **47**: 2442 - 2444
- Dannenbergh A.M. 1989. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. *Reviews of Infectious diseases* **11**: S369 - S377
- Davies P.D.O. 2003. Clinical Tuberculosis Third Edition. Oxford University Press Inc. New York.
- Davis S.D., Heywood V.H., Hamilton A.C (eds). 1994. Centres of Plant Diversity: A Guide and Strategy for their Conservation, Vol. 1, IUCN Publications, Cambridge.
- Deidda D., Lampis G., Fioravanti R., Biava M., Porretta G. C., Zanetti S., Pompei R. 1998. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intra-macrophagic *Mycobacterium tuberculosis* strains. *Antimicrobial Agents and Chemotherapy* **42**: 3035 - 3037
- De Logu A., Onnis V., Saggi B., Cocco M.T., 2002. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy* **49** (2): 275 - 282
- Department of Health, Republic of South Africa. 2007. National TB-Control Programme. TB Fact Sheet.
- De Smet P.A.G.M. 1997. The role of plant derived drugs and herbal medicines in healthcare. *Drugs* **54** (6): 801 - 840

- Diermeier H.F., Kaiser J.A., Yuda N. 1966. Safety evaluation of ethambutol. *Annals of New York Academic Science* **135**: 735 - 746
- Dimayuga R.E., Garcia S.K., 1991. Antimicrobial screening of medicinal plants from Baja California Sur, Mexico. *Journal of Ethnopharmacology* **31**:181-192
- Dimitris C., Gregory G., G., Laskarisb G., Robert V. 1985. Cyclopeptide alkaloids. New York. Volume. **26**, 299 - 306
- Don M., Shen C., Syr W., Ding Y., Sun C. 2006. Cytotoxic and aromatic constituents from *Salvia miltiorrhiza*. *Phytochemistry* **67**: 497 - 503
- Duke J.A. 2002. Handbook of medicinal herbs. Maryland, USA.
- Duman N. Cevikbas A., Johansson C. 2004. The effects of rifampicin and fluoroquinolones on tubercle bacilli within human macrophages. *International Journal of Antimicrobial Agents* **23** (4): 84 - 87
- Edward A. 2001. Pathogenesis *Justicia adhatoda* (ed) New, Old and Forgotten remedies. 210 - 220
- Eldeen I.M.S, van Staden J. 2007. Antimycobacterial activity of some trees used in South African traditional medicine. *South African Journal of Botany* **73** (2): 248 - 251
- Eloff J.N., 1998. A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria. *Planta Medica* **64**: 711 – 713
- Fadda G., Roe S.L. 1984. Recovery and susceptibility testing of *Mycobacterium tuberculosis* from extra pulmonary specimens by the BACTEC radiometric method. *Journal of Clinical Microbiology* **19** (5): 720 - 721
- Farnsworth N.R. 1984. The role of medicinal plants in drug development. In: Natural Products and Drug development. Bailliere, Tindal and Cox. London: 8 - 98
- Farnsworth N.R., Akerele O., Bingel A.S., Soejarto D.D., Guo Z. 1985. Medicinal plants in therapy. *WHO Bulletin* **63** (6): 965 - 981
- Fenton M.J. 1998. Macrophages and tuberculosis. *Current Opinion in Hematology* **5**(1): 72 - 78
- Ferebee S.H., 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. *Advance Tuberculosis Research* **17**: 28 - 106
- Ferrari M., Fornasiero M.C., Isetta A.M. 1990. MTT colorimeter assay for testing

- macrophage cytotoxic activity *in vitro*. *Journal of Immunological Methods* **131** (2): 165 - 172
- Ferreira A.M., Alves A.C., Costa M.A.C., Paul M.I. 1977 Naphthoquinone dimmers and trimers from *Euclea natalensis*. *Phytochemistry* **12**: 433 - 435
- Fischer N.H. 1996. Structure and activity of anti-tuberculosis natural products. *Review Latinoamer Quim* **24**: 65 - 68
- Fischer N.H., Lu T., Cantrell C.L., Castañeda-Acosa J., Quijano L., Franzblau S.G. 1998. Antimycobacterial evaluation of germacranilides. *Phytochemistry* **49**: 559 - 564
- Flamm R.K., Vojtko C., Chu D.T., Li Q., Beyer J., Hensey D., Ramer N., Clement J.J., Tanaka S.K. 1995. *In vitro* evaluation of ABT-719, a novel DNA gyrase inhibitor. *Antimicrobial Agents and Chemotherapy* **39**: 964 - 970
- Fouche G., Cragg G.M., Pillay P., Kolesnikova N. 2008. *In vitro* anticancer screening of South African plants. *Journal of Ethnopharmacology* **119**: 455 - 461
- Fourie B., Weyer K. 2000. TB and HIV-the deadly duo. *MRC News* **31**: 21 - 22
- Gao L.Y., Laval F., Lawson E.H., Groger R. K., Woodruff A., Morisaki J. H., Cox J. S., Daffe M., Brown E. J. 2003. Requirement for kasB in *Mycobacterium* mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. *Molecular Microbiology* **49**: 1547 - 1563
- Gautam R., Saklani A., Jachak S.A. 2007. Indian medicinal plants as a source of antimycobacterial agents. *Journal of Ethnopharmacology* **110**: 200 - 234
- Gaynor C., McCormack F.X., Voelker D.R., McGowan S.E., Schlesinger L.S. 1995. Pulmonary surfactant protein A mediates enhanced phagocytosis of *Mycobacterium tuberculosis* by a direct interaction with human macrophages. *Journal of Immunology* **155**: 5343 - 5351
- Gebhardt R. 2000. *In vitro* screening of plant extracts and phytopharmaceuticals: Novel approaches for the elucidation of active compounds and their mechanisms. *Planta Medica* **66**: 99 - 105
- Gibson R. 1993. Cpaie Sundew: *Drosera capensis*: know it and grow it. *Veld & Flora* **79**: 54 - 55
- Ginsburg A.S., Hooper N., Parrish N., Dooley K.E., Dorman S.E., Booth J., Diener

- West M., Merz W.G., Bishai W.R., Sterling T.R. 2003b. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. *Clinical Infectious Disease* **37**: 1448 - 1452
- Girling D.J. 1989. The chemotherapy of tuberculosis, In: Ratledge, C., Stanford, J.L., Grange, J.M., (Eds.), *Biology of the Mycobacterium tuberculosis*, **3**: 43 - 47
- Global TB Alliance Annual report 2004 - 2005; Stop TB Partnership Working Group on New Drugs for TB. Strategic Plan: 2006 - 2015
- Goren M.B. 1990. Mycobacterial fatty esters of sugars and sulfosugars. in *Handbook Lipid Res.* **6. Glycolipids, Phospholipids and Sulfoglycolipids**. Ed. Plenum Press: 363 - 461
- Grange J.M., Davey R.W. 1990. Detection of antituberculosis activity of plant extracts. *Journal of Applied Bacteriology* **68**: 587 - 591
- Grosset J.H. 1992. Treatment of tuberculosis in HIV Infection. *Tuberculosis and Lung Disease* **73**: 378 - 383
- Grosset J., Ji B. 1998. Experimental chemotherapy of mycobacterial diseases, 51 - 97. In Gangadharam P.R.J. and Jenkins P.A. *Mycobacteria, II Chemotherapy*. Chapman & Hall, New York.
- Gurib-Fakim A. 2006. Medicinal plants: Traditions of yesterday and drugs of tomorrow. *Molecular Aspects of Medicine* **27** (1): 1 - 93
- Gutierrez-Lugo M.T., Wang Y., Franzblau S.G., Timmermann B.N. 2005. Antitubercular sterols from *Thalia multiflora* Horkel ex Koernicke. *Phytotherapy Research* **19**: 876 - 880
- Haas W. 1996. The history of human tuberculosis [online]. University of Witwatersrand. Available from: <http://www.wits.ac.za/myco/html>.
- Handwerker S., Tomasz A. 1985. Antibiotic tolerance among clinical isolates of bacteria. *Revision of Infectious Diseases* **7**: 368 - 386
- Hamid R., Rotshteyn Y., Rabadi L., Parikh R. and Bullock P. 2004. Comparison of alamar blue and MTT assays for high through-put screening. *Toxicology in vitro* **18**: 703 - 710.
- Hazra B., Sur P., Roy D. K., Sur B., Banerjee A. 1984. Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice. *Planta Medica* **51**: 295 - 297

- Heifets L.B., Iseman M.D., Cook J.L., Lindholm-Levy P.J., Drupa I. 1985. Determination of *in vitro* susceptibility of *M. tuberculosis* to cephalosporins by radiometric and conventional methods. *Antimicrobial agents and Chemotherapy* **27**: 11 - 15
- Heinrich M., Gibbons S. 2001. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. *Journal of Pharmacy and Pharmacology* **53**: 425 - 432
- Herbert D., Paramasivan C.N., Venkatesan P., Kubendiran G., Prabhakar R., Mitchison D.A. 1996. Bactericidal action of ofloxacin, sulbactamampicilin, rifampin and isoniazid on logarithmic and stationary-phase cultures of *Mycobacterium tuberculosis*. *Antimicrobial Agents Chemotherapy* **40**: 2296 - 2299
- Heym B., Cole S.T. 1997. Multidrug resistance in *Mycobacterium tuberculosis*. *International Journal of Antimicrobial Agents* **8** (1): 61 - 70
- Hocking W.G., Golde D.W. 1979. The pulmonary-alveolar macrophage. *New England Journal of Medicine* **301**: 639
- Holdiness M.R. 1984. Clinical pharmacokinetics of the antituberculosis drugs. *Clinical Pharmacokinetics* **9**: 511 - 544
- Hosoya H., Marunouchi T. 1992. Differentiation and dedifferentiation of the Human Monocytic Leukemia cell line, U937. *Cell Structure and Function* **17**(5): 263 - 269
- Hostettmann K., Marston A. 2002. Twenty years of research into medicinal plants: results and perspectives. *Phytochemical Reviews* **1**: 275 - 285
- Houghton P.J., Woldemariam T.Z., Watanabe Y., Yates M. 1999. Activity against *Mycobacterium tuberculosis* of alkaloid constituents of Angostura bark, *Galipea officinalis*. *Planta Medica* **65**: 250 - 254
- Horne N. 1996. Tuberculosis and other mycobacterial diseases. In Cook G.C., Manson's Tropical Diseases. pp 971 - 1015
- Hu Y., Coates A.R., Mitchison D.A. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy* **47**: 653 - 657
- Huang P.L., Dawson T.M., Bredt D.S., Snyder S.H., Fishman M.C. 1993. Targeted

- disruption of the neuronal nitric oxide synthase gene. *Cell* 75(7): 1273 - 1282
- Hutchings A., Scott A.H., Lewis G., Cunningham A.B. 1996. *Zulu medicinal plants: an inventory*. University of Natal Press, Pietermaritzburg. Ibid J. 1983. Flavonoids from *Dodonaea viscosa*. *Phytochemistry* 22: 1253 - 1256
- Jackson W.P.U. 1990. Origins and meanings of names of South African plant genera. University of Cape Town.
- Jakupovic J., Klenmeyer H., Bohlmann F., Graven E. 1988. Glaucolides and guaianolides from *Atrémisia afra*. *Phytochemistry* 27: 1129 - 1134
- Jimenez-Arellanes A., Meckes M., Ramirez R., Torres J., Luna-Herrera J. 2003. Activity against multidrug-resistant *Mycobacterium tuberculosis* in Mexican plants used to treat respiratory diseases. *Phytotherapy Research* 17: 903 - 908
- Jindani A., Dore C.J., Mitchison D.A. 2003. Bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. *American Journal of Respiratory Care Medicine* 167: 1348 - 1354
- Joklik W.K., Willet H.P., Amos D.B. 1968. Mycobacteriaceae In: Zinsser Microbiology, 17th Ed. Appleton-century-crafts, New York. 651 - 664
- Jones P.B., Parrish N.M., Houston T.A., Stapon A., Bansal N.R., Dick J.D., Townsend C.A. 2000. A new class of antituberculosis agents. *Journal of Medical Chemistry* 43: 3304 - 3314
- Kamanzy A.K., Kone M., Terreaux C., Traore D., Hostettmann K., Dosso M. 2002. Evaluation of the antimicrobial potential of medicinal plants from the Ivory Coast. *Phytotherapy Research* 16 (5): 497 - 502
- Karaman S., Digrak M., Ravid U., Ilcim A. 2001. Antibacterial and antifungal activity of the essential oils of *Thymus revolutus* Celak from Turkey. *Journal of Ethnopharmacology* 76: 183 - 186
- Kirby G. C. 1996. Medicinal plants and the control of protozoal diseases, with particular reference to malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 90: 605 - 609
- Kochi. A. 1991. The global tuberculosis situation and the new control strategy of the World Health Organization. *Tuberculosis* 72: 1 - 6
- Kleeberg H.H., Koornhof H.J., Palmhert H. 1980. Laboratory manual of tuberculosis methods. Tuberculosis Research Institute, MRC, Pretoria,

South Africa.

- Klopper R.R., Smith G.F., Van Rooy J. 2002. The biodiversity of Africa. In: Baijnath H, Singh Y (eds) *Rebirth of Science in Africa: A Shared Vision for Life and Environmental Sciences. Contributions to the African Renaissance-Science Conference held at the Durban Botanic Gardens 25-29 March 2002*. Umdaus Press, Hatfield. pp 60 - 86
- Kraft C., Jenet-Siems K., Siems K., Jakupovic J., Mavi S., Bienzle U., Eich E. 2003. *In vitro* antiplasmodial evaluation of medicinal plants from Zimbabwe. *Phytotherapy Research* **17**: 123 - 128
- Labuschagne A. 2008. Antimycobacterial activity of seven herbaceous plants. Honours thesis. University of Pretoria. Department of Plant Science.
- Lall N., Meyer J.J.M. 1999. *In vitro* inhibition of drug-resistant and drug-sensitive strains of *Mycobacterium tuberculosis* by ethnobotanically selected South African plants. *Journal of Ethnopharmacology* **66**: 347 - 354
- Lall N., Meyer J.J.M. 2000. Antibacterial activity of water and acetone extracts of the roots of *Euclea natalensis*. *Journal of Ethnopharmacology* **72**: 313 - 316
- Lall N., Meyer J.J.M. 2001. Inhibition of drug-sensitive and drug-resistant strains of *Mycobacterium tuberculosis* by diospyrin, isolated from *Euclea natalensis*. *Journal of Ethnopharmacology* **78**: 213 - 216
- Lamidi M., Digiorgio C., Delmas F., Favel A., Mve-Mba C.E., Rondi M.L., Ollivier E., Nze-Ekekang L., Balansard G. 2005. *In vitro* cytotoxic, antileishmanial and antifungal activities of ethnobotanically selected Gabonese plants. *Journal of Ethnopharmacology* **102**: 185 - 190
- Li Y.-J., Petrofsky M., Bermudez L.E. 2002. *Mycobacterium tuberculosis* uptake by recipient host macrophages is influenced by environmental conditions in the granuloma of the infectious individuals and is associated with impaired production of Interleukin-12 and Tumor Necrosis Factor Alpha. *Infection and Immunology* **70** (11): 6223 - 6230
- Lin Y.-M., Zhou Y., Flavin M.T. Zhou L.-M. 2002. Chalcones and flavonoids as anti-tuberculosis agents. *Bioorganic and Medicinal Chemistry* **10**: 2795 - 2802
- Liu N.Q. Van der Kooy F., Verpoorte R. 2008. *Artemisia afra*: A potential flagship for African medicinal plants. *South African Journal of Botany* **75** (2): 185- 195

- Lechner D., Gibbons S., Bucar F. 2008. Modulation of isoniazid susceptibility by flavonoids in *Mycobacterium*. *Phytochemistry Letters* **1**: 71 - 75
- Long K.S., Poehlgarrd J., Kehrenberg C., Schwarz S., Vester B. 2006. The Cfr rRNA methyltransferase confers resistance to Phenicol, Lincosamides, Oxazolidinones, Pleuromutilins and Streptogramin A antibiotics. *Antimicrobial Agents and Chemotherapy* **50**: 2500 - 2505
- Lopez A., Hudson J.B., Towers G.H.N. 2001. Antiviral and antimicrobial activities of Colombian medicinal plants. *Journal of Ethnopharmacology* **77**: 189 - 196
- Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. 2006. Combinations of R₂₀₇₉₁₀ with drugs used to treat MDR-TB have the potential to shorten treatment duration. *Antimicrobial Agents and Chemotherapy* **50** (11): 3543 - 3547
- Lurie M.N., Carter E.J., Cohen J., Flanigan T.P. 2004. Directly observed therapy for HIV/tuberculosis co-infection. *The Lancet Infectious Diseases* **4**: 137 – 138
- Mabusela W.T., Vries F.A., Bitar El. H., Klaasen J.A., Bodo B., Johnson Q., 2005. An antifungal active extract from the aerial parts of *Galenia africana*. 11th NAPRECA Symposium Book of Proceedings, Antananarivo, Madagascar. pp 123 - 131
- Mabogo D.E.N. 1990. The ethnobotany of Vhavenda. MSc. Thesis. University of Pretoria. South Africa.
- Mander M. 1999. Marketing of Indigenous Medicinal Plants in South Africa: A case Study in KwaZulu-Natal: Summary of Findings. A publication of the Food and Agricultural Organisation of the United Nations, Forest Products Division.
- Mann A., Amupitan J.O., Oyewale A.O., Okogun J.I., Ibrahim K., Oladosu P., Lawson L., Olajide I., Nnamdi A. 2008. Evaluation of *in vitro* antimycobacterial activity of Nigerian plants used for treatment of respiratory diseases. *African Journal of Biotechnology* **7** (11): 1630 - 1636
- Marczak L., Kawiak A., Lojkowska E., M. Stobiecki M. 2005. Secondary metabolites in *in vitro* cultured plants of the genus *Drosera*. *Phytochemical analysis* **16** (3) 143 - 149
- Mativandlela S.P.N., Lall N., Meyer J.J.M. 2006. Antibacterial, antifungal and

- antitubercular activity of *Pelargonium reniforme* (CURT) and *Pelargonium sidoides* (DC) (Geraniaceae) root extracts. *South African Journal of Botany* **72**: 232 - 237
- Mativandlela S.P.N., Meyer J.J.M., Hussein A.A., Lall N. 2007. Antitubercular activity of isolated compounds from *Pelargonium sidoides*. *Pharmaceutical Biology* **45** (8): 645 - 650
- Mativandlela S.P.N., Meyer J.J.M., Hussein A.A., Houghton P.J., Hamilton C.J Lall N. 2008. Activity against *Mycobacterium smegmatis* and *M. tuberculosis* by extracts of South African medicinal plants. *Phytotherapy Research* **22** (6): 841 - 845
- Megehee J., Lundrigan M. 2007. Temporal expression of *Mycobacterium smegmatis* respiratory terminal oxidase. *Canadian Journal of Microbiology* **53**: 459 - 460
- Moran M., Ropars A. L., Guzman J., Diaz J., Garrison, C. 2005. The new landscape of neglected disease drug development.
- Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunological Methods* **65**: 55 - 63
- Mossa J.S. 1985. Phytochemical and biological studies on *Artemisia abyssinica*, an antidiabetic herb used in Arabian folk medicine. *Fitoterapia* **56**: 311 - 314
- McCune R.M., Tompsett R. 1956. Fate of *Mycobacterium tuberculosis* in mouse tissues as determined by the microbial enumeration technique. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. *Journal of Experimental Medicine* **104**: 737 - 762
- McCutcheon A.R., Strokes R.W., Thorson L.M., Ellis S.M., Hancock R.E.W., Towers G.H.N. 1997. Anti-mycobacterial screening of British Columbian medicinal plants. *International Journal of Pharmacognosy* **35**: 77 - 80
- McGaw L.J., Jager A.K., van Steden J. 2000. Antibacterial, antihelminthic and anti amoebic activity in South African medicinal plants. *Journal of Ethnopharmacology*, **72** (1-2): 247 - 263
- McGaw L.J., Lall N., Meyer J.J.M., Eloff J.N. 2008. The potential of South African plants against *Mycobacterium* infections. *Journal of Ethnopharmacology*, **119** (3): 482 - 500

- McKinney J.D. 2000. *In vivo* veritas: the search for TB drug targets goes live. *Nature Medicine* **6**: 1330 - 1333
- McKinney J.D., Honer zu Bentrup K., Munoz-Elias E.J., Miczak A., Chen B., Chan W.T., Swenson D., Sacchettini J.C., Jacobs W.R., Russel D.G. 2000. Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature Medicine* **406**: 735 - 738
- Middlebrook G., Reggiards Z., Tigertt W.D. 1977. Automable radiometric detection of growth of *Mycobacterium tuberculosis* in selective media. *American Review of Respiratory Disease* **115**: 1067 - 1069
- Mitchison D.A. 1979. Basic mechanisms of chemotherapy. *Chest* **76**: 771 - 781
- Mitchison D.A. 1980. Treatment of tuberculosis. The Mitchell lecture 1979. *Journal of Royal College Physicians of London* **14**: 91 - 99
- Mitchison D.A. 1984. Drug resistance in mycobacteria. *British Medical Bulletin* **40** (1): 84 - 90
- Mitchison D.A. 1992. The Garrod Lecture. Understanding the chemotherapy of tuberculosis-current problems. *Journal of Antimicrobial and Chemotherapy* **29**: 477 - 493
- Mitchison D.A. 1996. Pyrazinamide on the antituberculosis drug frontline. *Nature Medicine* **2** (6): 635 - 636
- Mitchison D.A., Selkon J.B. 1996. The bactericidal activities of antituberculosis drugs. *American Review of Tuberculosis* **74**: 109 - 116
- Mitscher L.A., Leu R., Bathala M.S., Wu W.N., Beal J.L. 1972. Antimicrobial agents from higher plants. **1**. Introduction, rationale and methodology. *Lloydia* **35**: 152 - 166
- Mitscher L.A., Park Y.H., Clarke D., Clarke III G.W., Hammersfahr P.D., Wu W.N., Beal J.L. 1978. Antimicrobial agents from higher plants. An investigation of *Hunnemannia fumariaefolia* pseudoalcoholates of sanguinarine and chelerythrine. *Lloydia* **42**: 145 - 150
- Mitscher L.A., Baker W.R. 1998. A search for novel chemotherapy against tuberculosis amongst natural products. *Pure Applied Chemistry* **70**: 365 - 371
- Miyazaki E., Miyazaki M., Chen J.M., Chaisson R.E., Bishai W.R. 1999. Moxifloxacin, a new 8-methoxyquinolone, is active in a mice model of

- tuberculosis. *Antimicrobial Agents and Chemotherapy* **43**: 85 - 89
- Miyaichi Y., Imoto Y., Tomimori T., Lin Chun Ching. 1987. Studies on the constituents of *Scutellaria* species (IX). On the flavonoid constituents of the roots of *Scutellaria indica* L. *Chemical and Pharmaceutical Bulletin* **35** (9): 3720 - 3725
- Miyaichi Y., Hanamitsu E., Kizu H., Tomimori T. 2006. Studies on the constituents of *Scutellaria* species (XXII). Constituents of the roots of *Scutellaria amabilis* HARA. *Chemical Pharmacology Bulletin* **54** (4): 425 - 441
- Miyaichi Y., Morimoto T., Yaguchi K., Kizu H. 2006. Studies on the constituents of *Scutellaria* species (XXII). Constituents of the leaves of *Scutellaria strigillosa* Hemley. *Journal of Natural Medicine* **60**: 157 - 158
- Miyazaki E., Miyazaki M., Chen J. M., Chaisson R. E., Bishai W. R. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. *Antimicrobial Agents and Chemotherapy* **43**, 85 - 89
- Moran M., Ropars A.L., Guzman J., Diaz J., Garrison C. 2005. The new landscape of neglected disease drug development (Wellcome Trust).
- Mpiana P.T., Mudogo V., Tshibangu D.S.T., Kitwa E.K., Kanangila A.B., Lumbu J.B.S., Ngbolua K.N., Atibu E.K., Kakule M.K. 2008. Antisickling activity of anthocyanins from *Bombax pentadrum*, *Ficus capensis* and *Ziziphus mucronata*: Photodegradation effect. *Journal of Ethnopharmacology* **120** (3): 413 - 418
- Mukherjee PK. 2003. GMP for Indian Systems of Medicine. In: Mukherjee P.K., and Verpoorte R. eds. *GMP for Botanicals: Regulatory and Quality Issues on Phytomedicines*, Business Horizons, New Delhi. pp 99 - 112
- Mukherjee J.S., Rich M.L., Soccia A.R., Joseph J.K., Virú F.A. 2004. Programmes and principles in treatment of multidrug-resistant tuberculosis. *Lancet* **363**: 474 - 481
- Musabayane C.T., Mahlalela N., Shode F.O., Ojewole J.A.O. 2005. Effects of *Syzygium cordatum* (Hochst.) [Myrtaceae] leaf extract on plasma glucose and hepatic glycogen in streptozotocin-induced diabetic rats. *Journal of Ethnopharmacology* **97** (3): 485 - 490

- Ndhlala A.R., Muchuweti M., Mupure C., Chitindingu K., Murenje T., Kasiyamhuru A., Benhura M.A. 2007. Phenolic content and profiles of selected wild fruits of Zimbabwe: *Ximenia caffra*, *Artobotrys brachypetalus* and *Syzygium cordatum*. *Internationaal Journal of Food Science and Technology* **43** (8): 1333 - 1337
- Nathan C., Shiloh M.U. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. *Proceedings of the National Academy of Sciences USA*. **97**: 8841 - 8848
- Neu H.C. 1987. Clinical use of the quinolones. *The Lancet Infectious Disease* **2**: 1319 - 1322
- Newman D.J., Cragg G.M., Snader K.M. 2003. Natural products as sources of new drugs over the period 1981 – 2002. *Journal of Natural Products* **66**: 1022 - 1037
- Newton G.L., Av-Gay Y., Fahey R.C. 2000. A novel mycothiol-dependent detoxification pathway in mycobacteria involving mycothiol-S-conjugate amidase. *Biochemistry* **39**: 10739 - 10746
- Newton S.M., Lau C., Wright C.W. 2000. A review of antimycobacterial natural products. *Phytotherapy Research* **14**: 302 - 322
- Newton G.L., Fahey R.C. 2002. Mycothiol Biochemistry. *Archives in Microbiology*, **178** (6): 388 - 394
- Newton S.M., Lau C., Gurcha S.S., Besra G.S., Wright C.W. 2002. The evaluation of forty-three plant species for *in vitro* antimycobacterial activities; isolation of active constituents from *Psoralea corylifolia* and *Sanguinaria canadensis*. *Journal of Ethnopharmacology* **79**: 57 - 67
- Niederweis M., Ehrh S., Heinz C., Klöcker U., Swiderek K. M., Riley L. W. Benz R. 1999. Cloning of the *mspA* gene encoding the porin from *Mycobacterium smegmatis*. *Molecular Microbiology* **33**: 933 - 945
- Nigro S.A., Makunga N.P., Grace O.M. 2004. Medicinal plants at the ethnobotany biotechnology interface in Africa. *South African Journal of Botany* **70** (1): 89 - 95
- Nikonenko B.V., Samala R., Einck L., Nacy C.A. 2004. Rapid, simple *in vivo* screen for new drugs active against *Mycobacterium tuberculosis*. *Antimicrobial*

- Agents and Chemotherapy* **48**: 4550 - 4555
- O'Brien R.J., Nunn P.P. 2001. The need for new drugs against tuberculosis. Obstacles, opportunities and next steps. *American Journal of Respiration and Critical Care Medicine* **163**: 1055 - 1058
- Okunade A.L., Elvin-Lewis M.P., Lewis W.H. 2004. Natural antimycobacterial metabolites: current status. *Phytochemistry* **65**: 1017 - 1032
- Oleksijew A., Meulbroek J., Ewing P., Jarvis K., Mitten M., Paige L., Tovcimak A., Nukkula M., Chu D., Alder J.D. 1998. *In vivo* efficacy of ABT-255 against drug-sensitive and resistant *Mycobacterium tuberculosis* strains. *Antimicrobial Agents and Chemotherapy* **42**: 2674 - 2677
- Orme I. 1993. Immunity to mycobacteria. *Current Opinion in Immunology* **5** (4): 497 - 502
- Orme I. 2001. Search for new drugs for treatment of tuberculosis. *Antimicrobial Agents and Chemotherapy* **45** (7): 1943 - 1946
- Osman S.A., Abdalla A.A., Alaib M.O. 1983. Synthesis of sulfanilamido naphthoquinones as potential antituberculous agents. *Journal of Pharmacology Science* **72**: 68 - 71
- Palmer E., Pitman N. 1972. Trees of Southern Africa. A. A. Balkema, Cape Town, South Africa.
- Palombo E.A., Semple S.J. 2001. Antibacterial activity of traditional Australian medicinal plants. *Journal of Ethnopharmacology* **77**: 151 - 157
- Paramasivan C.N., Sulochana S., Kubendiran G., Vnekatesan P., Mitchison D.A. 2005. Bactericidal action of gatifloxacin, rifampicin and isoniazid on logarithmic and stationary-phase cultures of *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy* **49**: 627 - 631
- Parrish N.M., Ko C.G., Hughes M.A., Townsend C.A., Dick J.D. 2004. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in *Mycobacterium bovis* BCG. *Journal of Antimicrobial and Chemotherapy* **54**: 722 - 729
- Patel M.P., Blanchard J.S. 1999. Expression, purification, and characterization of *Mycobacterium tuberculosis* mycothione reductase *Biochemistry* **38**: 11827 - 11833

- Patel M.P., Blanchard J.S. 2001. *Mycobacterium tuberculosis* mycothione reductase: pH dependence of the kinetic parameters and kinetic isotope effects. *Biochemistry* **40** (17): 5119 - 5126
- Pauli G.F., Case R.J., Inui T., Wang Y., Cho S., Fischer N.H., Franzblau S.G. 2005. New perspectives on natural products in TB drug research. *Life Sciences* **78**: 485 - 494
- Penna C., Marini S., Vivot E., Cruanes M.C., De D Munoz J., Cruanes J., Ferraro G., Gutkind G., Martino V. 2001. Antimicrobial activity of Argentine plants used in the treatment of infectious diseases. Isolation of active compounds from *Sebastiania brasiliensis*. *Journal of Ethnopharmacology* **77**: 39 - 40
- Petrella S., Cambau E., Chauffour A., Adries K., Jarlier V., Sougakoff W. 2006. Genetic basis for natural and acquired resistance to the diarylquinoline R 207910 in mycobacteria. *Antimicrobial Agents and Chemotherapy* **50**: 2853 - 2856
- Phillipson J.D. 2001. Phytochemistry and medicinal plants. *Phytochemistry* **56**: 237 - 243
- Pujol I. 1990. *Naturafrica - The Herbalist Handbook*. Jean Pujol Natural Healers, Foundation, Durban, South Africa.
- Pollock J. D., Williams D. A., Gifford M. A., Li L. L., Du X., Fisherman J., Orkin S. H., Doerschuk C. M., Dinauer M. C. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production *Nature Genetics* **9**: 202
- Potterat O., Hamburger M. 2008. Drug discovery and development with plant-derived compounds. *Progress in Drug Research* **65**: 45 - 118
- Quenelle D.C, Winchester G.A, Staas J.K. 2001. Treatment of tuberculosis using a combination of sustained-release Rifampin-loaded microspheres and oral dosing with Isoniazid. *Antimicrobial Agents and Chemotherapy* **45**: 1637 - 1644
- Ragno R., Marshall G. R., Di Santo R., Costi R., Massa S., Rompei R., Artico M. 2000. Antimycobacterial pyrroles: synthesis, anti- *Mycobacterium tuberculosis* activity and QSAR studies. *Bioorganic and Medicinal Chemistry* **8**: 1423 - 1432

- Ramaswamy S., Musser J.M. 1998. Molecular genetic basis of antimycobacterial agent resistance in *Mycobacterium tuberculosis*. *Tubercle and Lung Disease* **79**(1): 3 - 29
- Rastogi N., Labrousse V., Goh K.S., Carvalho De Sousa J.P. 1991: Antimycobacterial spectrum of sparfloxacin 415 and its activities alone and in association with other drugs against *Mycobacterium avium* complex growing extracellularly and intracellularly in marine and human macrophages. *Antimicrobial Agents and Chemotherapy* **35**: 2473 - 2480
- Raviglone M.C, Snider D.E, Kochi A. 1995. Global epidemiology of tuberculosis. *Journal of the American Medical Association* **273**: 220 - 226
- Redo M.C., Rios J.L., Villar A. 2006. A review of some antimicrobial compounds isolated from medicinal plants reported in the literature 1978-1988. *Phytotherapy Research* **3** (4): 117 - 125
- Reichman L.B., Hersfield E.S. 2000. Tuberculosis. A comprehensive international approach. Marcel Dekker, Inc. New York.
- Rivero-Cruz I., Acevedo L., Guerrero J.A., Martínez S., Bye R., Pereda-Miranda R., Franzblau S., Timmermann B.N., Mata R. 2005. Antimycobacterial agents from selected Mexican medicinal plants. *Journal of Pharmacy and Pharmacology* **57** (9): 1117 - 1126
- Robinson H.J., Siegel H., Pietrowski J.J. 1954. Toxicity of pyrazinamide. *American Review of Tuberculosis* **70**: 423 - 429
- Rodriguez J.C., Ruiz M., Climent A., Royo G. 2001. *In vitro* activity of four fluoroquinolones against *Mycobacterium tuberculosis*. *International Journal of Antimicrobial Agents* **17**: 229 - 231
- Rom W.N., Garay S. 1996. Tuberculosis. Little, Brown and Company, Inc. New York.
- Ruan Z.P., Zhang L.L., Lin Y.M. 2008. Evaluation of the antioxidant activity of *S. cumini* leaves. *Molecules* **13** (10): 2545 - 2556
- Sachdev K., Kulshreshtha D.K. 1984. Dodonic acid, a new diterpenoid from *Dodonaea viscosa*. *Planta Medica* **50**: 448 - 449
- Salie F., Eagles P.F.K, Leng H.M.J. 1996. Preliminary antimicrobial screening of four South African Asteraceae species. *Journal of Ethnopharmacology* **52**: 27 - 33

- Salmon-Chemin L., Buisine E., Yardley V., Kohler S., Debreu M.A., Landry V., Sergheraert C., Croft S.L., Krauth-Siegel L.R., Davioud-Charvet E. 2001. - 2-and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from *Trypanosoma cruzi*: Synthesis and correlation between redox cycling activities and *in vitro* cytotoxicity. *Journal of Medicinal Chemistry* **44**: 548 - 565
- Schlauer J. 1996. A dichotomous key to the genus *Drosera* L. (*Droseraceae*), *Carnivorous Plant Newsletter* **25**
- Schlunzen F., Pyeten E., Fucini P., Yonath A., Harms J.M. 2004. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from *Deinococcus radiodurans*. *Molecular Microbiology* **54**: 1287 - 1294
- Schulz V., Hansel R., Tyler V. 2001. *Rational Phytotherapy* 4th edition. Berlin: Springer Verlag.
- Scopio A., Zheng Y. 1996. Mutation in *pncA*, a gene encoding pyrazinamide or nicotinamide cause resistance to the antituberculosis drug PZA in tubercle bacillus. *Nature Medicine* **2** (6): 266 - 267
- Selwyn P.A., Hartel D., Lewis V.A. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *New England Journal of Medicine* **320**: 545 - 550
- Selwyn P.A., Sckell B.M., Alcabes P. 1992. High risk of active tuberculosis in HIV infected drug users with cutaneous energy. *Journal of the American Medical Association* **268**: 504 - 509
- Severi F., Benvenuti S., Costantino L., Vampa G., Melegari M., Antolini L. 1998. Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. *European Journal of Medicinal Chemistry* **33**: 859 - 866
- Shafi P.M., Rosamma M.K., Jamil K., Reddy P.S. 2002. Antibacterial activity of *Syzygium cumini* and *Syzygium travancoricum* leaf essential oils. *Fitoterapia* **73** (5): 414 - 416
- Shanmugam H., Anil K.K., Mukesh D. 2008. Synergism between natural products and antibiotics against infectious diseases. *Phytomedicine* **15**: 639 - 652
- Shinwari M.I., Khan M.A. 1998. Indigenous use of medicinal trees and shrubs of

- Margalla Hills National Park, Islamabad. *Journal of Forest Research* **48** (1 - 4):63 - 90
- Sheldon A.T. 2005. Antibiotic resistance: a survival strategy. *Clinical Laboratory Science Summer*. **18**: 170 - 180
- Siddiqi S.H., Libonati J.P., Middlebrook G. 1981. Evaluation of a rapid radiometric method for drug susceptibility testing of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* **13**: 908 - 913
- Silbernagel E., Spreitzer H., Buchbauer G. 1990. Non-volatile constituents of *Artemisia afra*. *Monatsch Chemistry* **121** (5): 433 - 436
- Smith G.F., Van Wyk A.E. 2002. Regions of Floristic Endemism in Southern Africa: A Review with Emphasis on Succulents. Umdaus Press, Pretoria.
- Snider S.H., Libonati J.P., Middlebrook, G. 1981. Evaluation of a rapid radiometric method for drug susceptibility testing of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* **18**: 689 - 696
- Sokmen A., Jones B.M., Erturk M. 1999. The *in vitro* antibacterial activity of Turkish medicinal plants. *Journal of Ethnopharmacology* **67**: 79 - 86
- Spies H.S.C., Steenkamp D.J. 1994. Novel thiols of intracellular pathogens: identification of othiol A in *Leishmania donovani* and structural analysis of a novel thiol from *Mycobacterium bovis*. *European Journal of Biochemistry* **224**: 203 - 213
- Steele J.H., Rammey A.F. 1958. Animal tuberculosis. *Annals of Internal Medicine* **116**: 937 - 994
- Steenkamp V., Fernandes A.C., Van Rensburg C.E.J. 2007. Screening of Venda medicinal plants for antifungal activity against *Candida albicans* *South African Journal of Botany* **73**: 256 - 258
- Stover C.K., Warrenner P., Van Devanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., 2000. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* **405**: 962 - 966
- Su B.N., Park E.J., Vigo J.S., Graham J.G., Cabieses F., Fong H.S.F., Pezzuto J.M., Kinghorn A.D. 2003. Activity-guided isolation of the chemicals constituents of *Muntingia calabura* using a quinone reductase induction assay.

- Phytochemistry* **63**(3): 335 - 341
- Suksamrarn S., Narisara A., Suwannapoch A., Wong A., Phakhodee O., Janthana A., Thanuhiranlert A., Piniti A., Ratananukul A., Chimnoi B., Suksamrarn A. 2003. Antimycobacterial activity of prenylated xanthenes from the fruits of *Garcinia mangostana*. *Chemical Pharmaceutical Bulletin* **51** (7): 857 - 859
- Sulochana S., Rahman F., Paramasivan C.N. 2005. *In vitro* activity of fluoroquinolones against *Mycobacterium tuberculosis*. *Journal of Chemotherapy* **17**: 169 - 173
- Svetaz L., Agüero M.B., Alvarez S., Luna L., Feresin G., Derita M., Tapia A., Zacchino S. 2007. Antifungal activity of *Zuccagnia punctata* Cav.: Evidence for the mechanism of action. *Planta Medica* **73** (10): 1074 - 1080
- Taniguchi H. 2000. Molecular mechanisms of multidrug resistance in *Mycobacterium tuberculosis*. *Journal of Occupational Health* **27** (3): 269 - 282
- TB Alliance. 2007. Advances Two Drugs In Clinical Trials On Path To Faster, Better Tuberculosis Treatments Trailblazing Phase III Trial Seeks to Shorten TB Treatment: Novel Candidate in Phase II Offers Hope for More Effective, Simpler Cure 11/08/2007 | News Release.
- Theunis F.G., Isabel I., Snyckers F.O. 1992. Folk Medicine: a viable starting point for pharmaceutical research. *South African Journal of Science*. **88**: 190 - 192
- Tripathi R.P., Tewari N., Dwivedi N., Tiwari V.K. 2005. Fighting tuberculosis: an old disease with new challenges. *Medicinal Research Review* **25**: 93 - 131
- Trivedi A.R., Dodiya D.K., Ravat N.R., Shah V.H. 2008. Synthesis and biological evaluation of some new pyrimidines via a novel chalcone series. *ARKIVOC* **11**: 131 - 141
- Tsukamura M., Nakamura E., Yoshii S., Amano H. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8₂8₀) on pulmonary tuberculosis. *American Review of Respiration Disease* **131**: 352 - 356
- Tyagi S., Nuermberger E., Yoshimatsu T., Williams K., Rosenthal I., Lounis N., Bishai W., Grosset J. 2005. Bactericidal activity of the nitroimidazopyran PA 8₂₄ in a murine model of tuberculosis. *Antimicrobial Agents and Chemotherapy* **49**: 2289 - 2293
- Uberti E., Martinelli E.M., Pifferi G., Gagliardi L. 1990. HPLC analysis of *n*-docosyl

- ferulate in *Pygeum africanum* extracts and pharmaceutical formulations. *Fitoterapia* **61** (4): 342 - 347
- Van Puyvelde L., Ntawukiliyaya J.D., Portaels F. 1994. *In vitro* inhibition of mycobacteria by Rwandese medicinal plants. *Phytotherapy Research* **8**: 65- 69
- Van Wyk B.E., Van Oudtshoorn B., Gericke N. 1997. Medicinal plants of South Africa. Briza Publications. South Africa.
- Van Wyk B.E., Wink M. 2004. Medicinal plants of the world. Briza Publications. South Africa.
- Van Wyk B.E., Gericke N. 2000. People's plants. A guide to useful plants of southern Africa. Briza Publications. South Africa.
- Velasco-Velazquez M.A., Barrera D., Gonzalez-Arenaz A., Agramonte-Hevia J. 2003. Macrophage-*Mycobacterium tuberculosis* interactions: role of complement receptor 3. *Microbial Pathogenesis* **35** (3): 125 - 131
- Vries F.A., Bitar H.E.L., Green I.R., Klassen J.A., Mabusela W.T., Bodo B., Johnson Q. An antifungal extract from the aerial parts of *Galenia africana*. 2005. 11th Napreca Symposium Book of Proceedings Antananarivo Madagascar: 123 - 131
- Watt C., Breyer-Brandwyk M.G. 1962. The medicinal and poisonous plants of Southern and Eastern Africa. E & S. Livingstone LTD. Edinburgh and London, 449
- Wilson T.M., Collins D.M. 1996. AhpC, a gene involved in isoniazid resistance of the *Mycobacterium tuberculosis* complex. *Molecular Microbiology* **19** (5): 1025 - 1034
- Wijesekera R.O.B. 1991. The medicinal plant industry. INTECNOS Associates, Sri Lanka
- Weigenand O., Hussein A.A.H., Lall N., Meyer J.J.M. 2004. Antibacterial activity of naphthoquinones and triterpenoids from *Euclea natalensis* root bark. *Journal of Natural Products* **67**(11): 1936 - 1938
- Wollenweber E., Mann K., Valant-Vetschera K.M. 1989. External flavonoid aglycones in *Artemisia* and some further Anthemidae (Asteraceae). *Fitoterapia* **60** (5): 460 - 463
- World Health Organisation. 1996 Traditional Medicines. WHO Fact Sheet No 134.

- Geneva.
- World Health Organisation. 1999. World Report 1998. Office of World Health Reporting. Geneva, Switzerland.
- World Health Organisation. 2000. *Tuberculosis*. Fact Sheet number 104. World Health Organization: Geneva, Switzerland.
- World Health Organisation. 2001. *Global Tuberculosis Control*. World Health Organization: Geneva, Switzerland.
- World Health Organisation. 2003. Traditional Medicine Facts. Fact Sheet number 134. World Health Organization: Geneva, Switzerland.
- World Health Organisation. 2006. Tuberculosis Facts. WHO/HTM/STB/factsheet/2006.1
- World Health Organisation. 2007. *Tuberculosis*. Fact Sheet number 104, revised March 2007. World Health Organization: Geneva, Switzerland.
- World Health Organisation. 2008. *Global Tuberculosis Control*. World Health Organization: Geneva, Switzerland.
- Yelne M.B., Sharma P.C., Dennis T.J. 2001. Database on medicinal plants used in Ayurvede (Vol 2). First Edition, New Delhi CCRAs.
- Youmans A.S., Youmans G.P. 1948. The effect of "Tween-80" *in vitro* on the bacteriostatic activity of twenty compounds for *Mycobacterium tuberculosis* J. *Bacteriology* **56**: 245 - 252
- Young D.B.1994. Tuberculosis. Beating the bacillus. *Current Biology* **4** (4): 351 - 353
- Young D.B., Duncan K. 1995. Prospects for new interventions in the treatment and prevention of mycobacterial disease. *Annual Review of Microbiology* **49** (1): 641 - 673
- Zampini I.C., Vattuone M.A., Isla M.I. 2005. Antibacterial activity of *Zuccagnia punctata* Cav. ethanolic extracts. *Journal of Ethnopharmacology* **102** (3): 450 - 456
- Zakaria M. 1991. Isolation and characterization of active compounds from medicinal plants. *Asia Pac Journal of Pharmacology* **6**: 15 - 20
- Zhang Y. 2005. The magic bullets and tuberculosis drug targets. *Annual Review of Pharmacology Toxicology* **45**: 529 - 564
- Zheng Y.T., Chan W.L., Chan P., Huang H., Tam S.C. 2001. Enhancement of the anti



herpetic effect of trichosanthin by acyclovir and interferon. *Federation of European Biochemical Societies, Letters* **496**: 139 - 142

Zumla A., Grange J. 1998. Clinical review: tuberculosis. *British Medical Journal* **316**, 1962 - 1967

CHAPTER 11

ACKNOWLEDGEMENTS

I would like to thank the following persons and institutions:

Professor Namrita Lall, my supervisor, for her guidance, support and comments. Special thanks for her contribution during the research project, thesis write up and article publication.

Professor J.J. Marion Meyer, for giving me an opportunity to study in the Department of Plant Science, for his kind assistance, and critical comments.

Ms. Magda Nel for the identification of the plant species.

Traditional healers: Mr. Peter von Maltitz and Mr. Elias Mudau, for providing information on selected plants for the research.

The Research team of the Department of Plant Science, for their support.

Doctor Chris Hamilton (School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich), for his assistance during the research.

Doctor Tshilidzi Muthivhi (South African Blood Service, South Africa), for his kind assistance and comments during antimycobacterial assays.

Doctor Steve Olorunju (South African Medical Research Council, Biostatistics Unit Pretoria), for his guidance, comments and support during my study project.

The supportive staff of The South African Medical Research Council, Tuberculosis, Epidemiology and Intervention Research Unit, Pretoria. In particular Dr Martie van der Walt for giving me encouragement during write up.

Department of Health, Cluster: TB Control Management for providing the TB-statistics cases in South Africa.

Doctor Ahmed Hussein (Pharmacognosy and Chemistry of Medicinal Plants Lab, Pharmaceutical Sciences Department, National Research Centre, Egypt), for his kind assistance with regard to extraction, isolation, chromatography and spectroscopy techniques throughout the entire study.

Doctor Anita Mahapatra and Doctor Frank van der Kooy for providing naphthoquinone-compounds.

Mr. Eric Palmer, for kindly providing his technical assistance with NMR spectroscopy.

The National Research Foundation (NRF), the Innovation Funding, Royal Society Fund and the University of Pretoria for financial support.

My Beloved Grandmother Monica Athifhulufhelwi Mativandlela, for her spiritual support, my family for their encouragement, understanding, support, patience, kindness through difficult times.

Friends who encouraged and guided me during my entire study period.

I thank God for His blessings and protection everyday.

CHAPTER 12

APPENDICES - PUBLICATIONS

12.1 Publications resulting from this thesis:

Activity against *Mycobacterium smegmatis* and *M. tuberculosis* by extracts of South African medicinal plants. 2008. *Phytotherapy Research* **22**(6): 841 - 845

Activity of 7-methyljuglone derivatives against *Mycobacterium tuberculosis* and as subversive substrates for mycothiol disulfide reductase. 2007. *Biorganic Medicinal Chemistry* **15** (24): 7638 - 7646

12.2 Article submitted for review:

A new antimycobacterial chalcone isolated from *Galenia africana* L. var *africana*

Submitted March 2009: Journal of Natural Product

12.3 Chapter to be submitted in a book (In preparation)

Epidemiology, prevention and treatment of tuberculosis using medicinal plants and existing antituberculosis drugs

S.P.N Mativandlela and N. Lall

12.4 Conference presentation

12.4.1. 4th Advances in Synthesis and Chemical Biology Symposium, Dublin, UK. 5th December 2005

“Mechanistic studies of disulfide reductase inhibition by diospyrin, 7-methyljuglone and related anti-mycobacterial naphthoquinones isolated from *Euclea natalensis*”

S.P.N. Mativandlela, N. Lall, J.J.M. Meyer and C.J. Hamilton.

12.4.2. South African TB Conference, ICC Durban, South Africa. 1st - 4th July 2008

“Evaluation of flavonoid compounds alone and in combination against *Mycobacterium tuberculosis*”

S.P.N. Mativandlela, T. Muthivhi, M. van der Walt, N. Lall, J.J.M. Meyer and A.A. Hussein.

12.4.3. 39th Union World Conference on Lung Health. 16th – 20th October 2008. Palais des Congrès, Paris, France.

‘Evaluation of selected South African medicinal plants against *Mycobacterium smegmatis* and *M. tuberculosis* for treatment of tuberculosis’.

S.P.N. Mativandlela, M. van der Walt, N. Lall, J.J.M. Meyer, T. Muthivhi